At the news
? BEARISHIMPACT 7/10 S-3 filed Aug 17, 2026 at 17:00 ET
Indaptus Therapeutics filed an S-3 registration statement to register 58,895,000 shares of common stock for resale by selling stockholders, representing ~44.2% of shares outstanding. The company has no active clinical programs, having discontinued its Decoy20 study, and is evaluating strategic alternatives. The filing itself raises no new capital for the company but creates massive potential overhang from the selling stockholders, who can sell into the market at any time.
- Registers 58,895,000 shares for resale by selling stockholders, representing ~44.2% of 133,242,324 shares outstanding.
- No new capital raised for the company; all proceeds go to selling stockholders.
- Company has discontinued all clinical programs (Decoy20) and has no active development pipeline.
- Auditor's report includes a going concern explanatory paragraph.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access